Search
Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigational[A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the … [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384].
Aldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalThis recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon … Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.
Ropivacaine
go.drugbank.com/drugs/DB00296ApprovedInvestigationalRopivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin.
Synonyms: L-N-n-propylpipecolic acid-2,6-xylidideCilnidipine
go.drugbank.com/drugs/DB09232InvestigationalIt was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. … Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium
Imidafenacin
go.drugbank.com/drugs/DB09262InvestigationalIt is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. … It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.
Quinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigationalQuinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure. … [A184844] Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423]
Categories: Agents Acting on the Renin-Angiotensin SystemTemoporfin
go.drugbank.com/drugs/DB11630ApprovedIt was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
Dalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. … Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Products: FRAGMIN 5000IE P FO FER SI, FRAGMIN P FO 5000IE FER+SIMirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigationalMirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.